{"id":43244,"date":"2025-10-14T14:54:41","date_gmt":"2025-10-14T06:54:41","guid":{"rendered":"https:\/\/flcube.com\/?p=43244"},"modified":"2025-10-14T14:54:42","modified_gmt":"2025-10-14T06:54:42","slug":"beone-medicines-receives-fda-breakthrough-therapy-designation-for-sonrotoclax-in-relapsed-mantle-cell-lymphoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43244","title":{"rendered":"BeOne\u202fMedicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma"},"content":{"rendered":"\n<p><strong>BeOne Medicines Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ONC:NASDAQ\">NASDAQ: ONC<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG: 6160<\/a>; <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA: 688235<\/a>) announced today that the U.S. Food and Drug Administration (FDA) has granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> to its next\u2011generation BCL2 inhibitor, <strong>Sonrotoclax<\/strong>, for the treatment of adult patients with <strong>relapsed or refractory (R\/R) mantle cell lymphoma (MCL)<\/strong>. The designation represents the first BTD for Sonrotoclax and the second for BeOne\u2019s hematology portfolio.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-key-highlights\">Key Highlights<\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>Sonrotoclax (BCL2 inhibitor)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Adult R\/R mantle cell lymphoma (MCL)<\/td><\/tr><tr><td><strong>FDA Designations<\/strong><\/td><td>Breakthrough Therapy, Fast\u2011Track, Orphan Drug (MCL, WM, MM, AML)<\/td><\/tr><tr><td><strong>Pipeline Impact<\/strong><\/td><td>Second BTD for BeOne, reinforcing leadership in hematology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-what-the-designation-means\">What the Designation Means<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Development Pathway<\/strong> \u2013 Fast\u2011track review, potential priority status in clinical trials, and more frequent FDA interactions.<\/li>\n\n\n\n<li><strong>Clinical Momentum<\/strong> \u2013 Builds on earlier Fast\u2011Track and Orphan Drug approvals for Sonrotoclax in MCL, Waldenstr\u00f6m\u2019s macroglobulinemia (WM), multiple myeloma (MM), and acute myeloid leukemia (AML).<\/li>\n\n\n\n<li><strong>Strategic Advantage<\/strong> \u2013 Positions BeOne as a leading developer of targeted therapies for rare and high\u2011need hematologic malignancies.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-about-sonrotoclax\">About Sonrotoclax<\/h4>\n\n\n\n<p>Sonrotoclax is a <strong>next\u2011generation, potentially best\u2011in\u2011class BCL2 inhibitor<\/strong> designed to induce apoptosis in malignant B\u2011cells. Preclinical and early\u2011phase data demonstrate potent activity against MCL cells, including those resistant to standard therapies.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-about-beone-medicines\">About BeOne\u202fMedicines<\/h4>\n\n\n\n<p>BeOne\u202fMedicines is a global biotechnology company focused on discovering and developing innovative therapies for hematologic and solid\u2011tumor malignancies. The company\u2019s portfolio spans multiple therapeutic classes, with a particular emphasis on targeted small molecules and biologics.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h4>\n\n\n\n<p>This release contains forward\u2011looking statements regarding the FDA designations, clinical development plans, and potential market impact. These statements are based on current expectations and are subject to risks and uncertainties, including regulatory approval, clinical outcomes, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that the U.S. Food&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43248,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2092,34,16,847,3046,848],"class_list":["post-43244","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-beone-medicines","tag-breakthrough-therapy","tag-cancer","tag-hkg-6160","tag-nasdaq-onc","tag-sha-688235"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BeOne\u202fMedicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its next\u2011generation BCL2 inhibitor, Sonrotoclax, for the treatment of adult patients with relapsed or refractory (R\/R) mantle cell lymphoma (MCL). The designation represents the first BTD for Sonrotoclax and the second for BeOne\u2019s hematology portfolio.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43244\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeOne\u202fMedicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma\" \/>\n<meta property=\"og:description\" content=\"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its next\u2011generation BCL2 inhibitor, Sonrotoclax, for the treatment of adult patients with relapsed or refractory (R\/R) mantle cell lymphoma (MCL). The designation represents the first BTD for Sonrotoclax and the second for BeOne\u2019s hematology portfolio.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43244\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-14T06:54:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-14T06:54:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1404.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43244#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43244\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeOne\u202fMedicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma\",\"datePublished\":\"2025-10-14T06:54:41+00:00\",\"dateModified\":\"2025-10-14T06:54:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43244\"},\"wordCount\":307,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43244#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1404.webp\",\"keywords\":[\"BeOne Medicines\",\"Breakthrough therapy\",\"Cancer\",\"HKG: 6160\",\"NASDAQ: ONC\",\"SHA: 688235\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43244#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43244\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43244\",\"name\":\"BeOne\u202fMedicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43244#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43244#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1404.webp\",\"datePublished\":\"2025-10-14T06:54:41+00:00\",\"dateModified\":\"2025-10-14T06:54:42+00:00\",\"description\":\"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its next\u2011generation BCL2 inhibitor, Sonrotoclax, for the treatment of adult patients with relapsed or refractory (R\\\/R) mantle cell lymphoma (MCL). The designation represents the first BTD for Sonrotoclax and the second for BeOne\u2019s hematology portfolio.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43244#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43244\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43244#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1404.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1404.webp\",\"width\":1080,\"height\":608,\"caption\":\"BeOne\u202fMedicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43244#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeOne\u202fMedicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeOne\u202fMedicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma - Insight, China&#039;s Pharmaceutical Industry","description":"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its next\u2011generation BCL2 inhibitor, Sonrotoclax, for the treatment of adult patients with relapsed or refractory (R\/R) mantle cell lymphoma (MCL). The designation represents the first BTD for Sonrotoclax and the second for BeOne\u2019s hematology portfolio.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43244","og_locale":"en_US","og_type":"article","og_title":"BeOne\u202fMedicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma","og_description":"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its next\u2011generation BCL2 inhibitor, Sonrotoclax, for the treatment of adult patients with relapsed or refractory (R\/R) mantle cell lymphoma (MCL). The designation represents the first BTD for Sonrotoclax and the second for BeOne\u2019s hematology portfolio.","og_url":"https:\/\/flcube.com\/?p=43244","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-14T06:54:41+00:00","article_modified_time":"2025-10-14T06:54:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1404.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43244#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43244"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeOne\u202fMedicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma","datePublished":"2025-10-14T06:54:41+00:00","dateModified":"2025-10-14T06:54:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43244"},"wordCount":307,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43244#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1404.webp","keywords":["BeOne Medicines","Breakthrough therapy","Cancer","HKG: 6160","NASDAQ: ONC","SHA: 688235"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43244#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43244","url":"https:\/\/flcube.com\/?p=43244","name":"BeOne\u202fMedicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43244#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43244#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1404.webp","datePublished":"2025-10-14T06:54:41+00:00","dateModified":"2025-10-14T06:54:42+00:00","description":"BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its next\u2011generation BCL2 inhibitor, Sonrotoclax, for the treatment of adult patients with relapsed or refractory (R\/R) mantle cell lymphoma (MCL). The designation represents the first BTD for Sonrotoclax and the second for BeOne\u2019s hematology portfolio.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43244#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43244"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43244#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1404.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1404.webp","width":1080,"height":608,"caption":"BeOne\u202fMedicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43244#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeOne\u202fMedicines Receives FDA Breakthrough Therapy Designation for Sonrotoclax in Relapsed Mantle Cell Lymphoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1404.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43244"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43244\/revisions"}],"predecessor-version":[{"id":43249,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43244\/revisions\/43249"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43248"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43244"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43244"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}